SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Period	dileps
2015-12-31	-$26.80
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	-$2.80
2019-12-31	-$9.60
2020-12-31	-$5.15
2021-12-31	-$1.25
2022-12-31	-$1.47
2023-12-31	$1.40
2024-12-31	-$0.44

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SCYX	$0.99	+0.00%	0.36M
3
4
5

SCYNEXIS Inc. (SCYX) Earnings Per Share (EPS)

EPS (Earnings Per Share) Data

Get SCYNEXIS Inc. Data in Excel

More SCYX Financial Data